Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jul 17, 2007

Pharmacopeia Earns Milestone Payment in GSK Partnership

  • Pharmacopeia will receive a $500,000 milestone payment from GlaxoSmithKline as it has identified a lead compound for advancement six months ahead of schedule. This candidate is being evaluated as a treatment for inflammatory pain and will now enter lead optimization.

    Under the terms of the companies' collaboration, Pharmacopeia has already received $10 million from GSK and is entitled to an additional $5-million upon the completion of further early discovery activities. Pharmacopeia could also earn milestones totaling up to $83 million per program plus double-digit royalties.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »